Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975347 · ClinicalTrials.gov registry record · Phase 1
Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank
A Phase 1 study of Reproductive Disorders, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT04975347: Completed Phase 1 study of Reproductive Disorders, sponsored by Stephanie B. Seminara, MD.
NCT04975347 is a Phase 1 study of Reproductive Disorders that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04975347, a Phase 1 study of Reproductive Disorders, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in healthy subjects.
Primary Outcome
Change in LH pulse frequency before and during naloxone infusion
Conditions Studied
Interventions
- DRUG Naloxone
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2025-08-08 |
| Phase | Phase 1 |
What the finished NCT04975347 record still lists
NCT04975347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Reproductive Disorders appearing as the primary indexed condition, and to 1 intervention - of which Naloxone is the first listed.
NCT04975347 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04975347 about?
NCT04975347 is a clinical study titled "Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank". The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in healthy subjects.
What is the current status of trial NCT04975347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2022-06-03. Estimated completion is 2025-08-08.
What conditions does trial NCT04975347 study?
This clinical trial studies the following conditions: Reproductive Disorders.
What interventions are being tested in trial NCT04975347?
The interventions under investigation include: Naloxone (DRUG).
Who is sponsoring clinical trial NCT04975347?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975347 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04975347's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI